Artesunate induces ROS-dependent apoptosis via a Bax-mediated intrinsic pathway in Huh-7 and Hep3B cells

Experimental Cell Research

Volumn 347, Issue 2, 2016, Pages 251-260

  Pang, Yilin ^a   Qin, Guiqi ^a   Wu, Liping ^a   Wang, Xiaoping ^b   Chen, Tongsheng ^a  

^a SOUTH CHINA NORMAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF JINAN UNIVERSITY   (China)

Author keywords

Apoptosis; Artesunate; Bax; Caspases; Hepatocellular carcinoma cells; ROS

Indexed keywords

ACETYLCYSTEINE; ARTESUNATE; CASPASE 3; CASPASE 9; CYTOCHROME C; IRON; PHOSPHATIDYLSERINE; PIFITHRIN ALPHA; PROTEIN BAX; REACTIVE OXYGEN METABOLITE; ARTEMISININ DERIVATIVE; ION; PROTEIN BAK; PROTEIN P53;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME RELEASE; GENE SILENCING; HEPG2 CELL LINE; HUMAN; HUMAN CELL; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE; BIOLOGICAL MODEL; DRUG EFFECTS; METABOLISM; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL LINE;

APOPTOSIS; ARTEMISININS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; HUMANS; IONS; IRON; MODELS, BIOLOGICAL; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84992520880     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2016.06.012     Document Type: Article

References (64)

1. [1] Efferth, T., Dunstan, H., Sauerbrey, A., Miyachi, H., Chitambar, C.R., The anti-malarial artesunate is also active against cancer. Int. J. Oncol. 18 (2001), 767–773.
2. [2] Firestone, G.L., Sundar, S.N., Anticancer activities of artemisinin and its bioactive derivatives. Expert Rev. Mol. Med., 11, 2009, e32.
3. [3] Crespo-Ortiz, M.P., Wei, M.Q., Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug. J. Biomed. Biotechnol., 2012, 2012, 247597.
4. [4] Yang, Y., Zhang, X., Wang, X., Zhao, X., Ren, T., Wang, F., Yu, B., Enhanced delivery of artemisinin and its analogues to cancer cells by their adducts with human serum transferrin. Int. J. Pharm. 467 (2014), 113–122.
5. [5] Mercer, A.E., Copple, I.M., Maggs, J.L., O'Neill, P.M., Park, B.K., The role of heme and the mitochondrion in the chemical and molecular mechanisms of mammalian cell death induced by the artemisinin antimalarials. J. Biol. Chem. 286 (2011), 987–996.
6. [6] Efferth, T., Giaisi, M., Merling, A., Krammer, P.H., Li-Weber, M., Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells. PLoS One, 2, 2007, e693.
7. [7] Singh, N.P., Lai, H.C., Artemisinin induces apoptosis in human cancer cells. Anticancer Res. 24 (2004), 2277–2280.
8. [8] Zeng, Q.P., Zhang, P.Z., Artesunate mitigates proliferation of tumor cells by alkylating heme-harboring nitric oxide synthase. Nitric Oxide 24 (2011), 110–112.
9. [9] Shi, R., Cui, H., Bi, Y., Huang, X., Song, B., Cheng, C., Zhang, L., Liu, J., He, C., Wang, F., Artesunate altered cellular mechanical properties leading to deregulation of cell proliferation and migration in esophageal squamous cell carcinoma. Oncol. Lett. 9 (2015), 2249–2255.
10. [10] Berdelle, N., Nikolova, T., Quiros, S., Efferth, T., Kaina, B., Artesunate induces oxidative DNA damage, sustained DNA double-strand breaks, and the ATM/ATR damage response in cancer cells. Mol. Cancer Ther. 10 (2011), 2224–2233.
11. [11] Button, R.W., Lin, F., Ercolano, E., Vincent, J.H., Hu, B., Hanemann, C.O., Luo, S., Artesunate induces necrotic cell death in schwannoma cells. Cell Death Dis., 5, 2014, e1466.
12. [12] Chen, K., Shou, L.-M., Lin, F., Duan, W.-M., Wu, M.-Y., Xie, X., Xie, Y.-F., Li, W., Tao, M., Artesunate induces G2/M cell cycle arrest through autophagy induction in breast cancer cells. Anticancer Drugs 25 (2014), 652–662.
13. [13] Du, J.H., Zhang, H.D., Ma, Z.J., Ji, K.M., Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo. Cancer Chemother. Pharmacol. 65 (2010), 895–902.
14. [14] Jeong, D.E., Song, H., Lim, S., Lee, S., Lim, J., Nam, D., Joo, K., Jeong, B., Jeon, S., Choi, H., Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis. Oncotarget 6 (2015), 33046–33064.
15. [15] Eling, N., Reuter, L., Hazin, J., Hamacher-Brady, A., Brady, N.R., Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. Oncoscience, 2, 2015, 517.
16. [16] Krishna, S., Bustamante, L., Haynes, R.K., Staines, H.M., Artemisinins: their growing importance in medicine. Trends Pharmacol. Sci. 29 (2008), 520–527.
17. [17] Efferth, T., Romero, M.R., Wolf, D.G., Stamminger, T., Marin, J.J., Marschall, M., The antiviral activities of artemisinin and artesunate. Clin. Infect. Dis. 47 (2008), 804–811.
18. [18] Hou, J., Wang, D., Zhang, R., Wang, H., Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin. Cancer Res. 14 (2008), 5519–5530.
19. [19] Dell'Eva, R., Pfeffer, U., Vene, R., Anfosso, L., Forlani, A., Albini, A., Efferth, T., Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate. Biochem. Pharmacol. 68 (2004), 2359–2366.
20. [20] Cui, C., Feng, H., Shi, X., Wang, Y., Feng, Z., Liu, J., Han, Z., Fu, J., Fu, Z., Tong, H., Artesunate down-regulates immunosuppression from colorectal cancer Colon26 and RKO cells in vitro by decreasing transforming growth factor β 1 and interleukin-10. Int. Immunopharmacol. 27 (2015), 110–121.
21. [21] Efferth, T., Activation of Mitochondria-Driven Pathways by Artemisinin and Its Derivatives, Mitochondria: The Anti-cancer Target for the Third Millennium. 2014, Springer, 135–150.
22. [22] del Pilar Crespo, M., Avery, T.D., Hanssen, E., Fox, E., Robinson, T.V., Valente, P., Taylor, D.K., Tilley, L., Artemisinin and a series of novel endoperoxide antimalarials exert early effects on digestive vacuole morphology. Antimicrob. Agents Chemother. 52 (2008), 98–109.
23. [23] O'Neill, P.M., Barton, V.E., Ward, S.A., The molecular mechanism of action of artemisinin – the debate continues. Molecules 15 (2010), 1705–1721.
24. [24] Lu, J.-J., Chen, S.-M., Zhang, X.-W., Ding, J., Meng, L.-H., The anti-cancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells. Investig. New Drugs 29 (2011), 1276–1283.
25. [25] Liu, W.M., Gravett, A.M., Dalgleish, A.G., The antimalarial agent artesunate possesses anticancer properties that can be enhanced by combination strategies. Int. J. Cancer 128 (2011), 1471–1480.
26. [26] Gao, X., Luo, Z., Xiang, T., Wang, K., Li, J., Wang, P., Dihydroartemisinin induces endoplasmic reticulum stress-mediated apoptosis in HepG2 human hepatoma cells. Tumori 97 (2011), 771–780.
27. [27] Stockwin, L.H., Han, B., Yu, S.X., Hollingshead, M.G., ElSohly, M.A., Gul, W., Slade, D., Galal, A.M., Newton, D.L., Artemisinin dimer anticancer activity correlates with heme-catalyzed reactive oxygen species generation and endoplasmic reticulum stress induction. Int. J. Cancer 125 (2009), 1266–1275.
28. [28] Cheng, R., Li, C., Li, C., Wei, L., Li, L., Zhang, Y., Yao, Y., Gu, X., Cai, W., Yang, Z., Ma, J., Yang, X., Gao, G., The artemisinin derivative artesunate inhibits corneal neovascularization by inducing ROS-dependent apoptosis in vascular endothelial cells. Investig. Ophthalmol. Vis. Sci. 54 (2013), 3400–3409.
29. [29] Hamacher-Brady, A., Stein, H.A., Turschner, S., Toegel, I., Mora, R., Jennewein, N., Efferth, T., Eils, R., Brady, N.R., Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomal reactive oxygen species production. J. Biol. Chem. 286 (2011), 6587–6601.
30. [30] Michaelis, M., Kleinschmidt, M.C., Barth, S., Rothweiler, F., Geiler, J., Breitling, R., Mayer, B., Deubzer, H., Witt, O., Kreuter, J., Doerr, H.W., Cinatl, J., Cinatl, J. Jr., Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines. Biochem. Pharmacol. 79 (2010), 130–136.
31. [31] Beccafico, S., Morozzi, G., Marchetti, M.C., Riccardi, C., Sidoni, A., Donato, R., Sorci, G., Artesunate induces ROS- and p38 MAPK-mediated apoptosis and counteracts tumor growth in vivo in embryonal rhabdomyosarcoma cells. Carcinogenesis 36 (2015), 1071–1083.
32. [32] Zhou, C., Pan, W., Wang, X.P., Chen, T.S., Artesunate induces apoptosis via a Bak-mediated caspase-independent intrinsic pathway in human lung adenocarcinoma cells. J. Cell. Physiol. 227 (2012), 3778–3786.
33. [33] Qin, G., Wu, L., Liu, H., Pang, Y., Zhao, C., Wu, S., Wang, X., Chen, T., Artesunate induces apoptosis via a ROS-independent and Bax-mediated intrinsic pathway in HepG2 cells. Exp. Cell Res. 336 (2015), 308–317.
34. [34] Youle, R.J., Strasser, A., The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9 (2008), 47–59.
35. [35] Dong, H.Y., Wang, Z.F., Antitumor effects of artesunate on human breast carcinoma MCF-7 cells and IGF-IR expression in nude mice xenografts. Chin. J. Cancer Res. 26 (2014), 200–207.
36. [36] Zhang, P., Luo, H.S., Li, M., Tan, S.Y., Artesunate inhibits the growth and induces apoptosis of human gastric cancer cells by downregulating COX-2. Onco Targets Ther. 8 (2015), 845–854.
37. [37] Liu, L., Zuo, L.F., Zuo, J., Wang, J., Artesunate induces apoptosis and inhibits growth of Eca109 and Ec9706 human esophageal cancer cell lines in vitro and in vivo. Mol. Med. Rep. 12 (2015), 1465–1472.
38. [38] Papanikolaou, X., Johnson, S., Garg, T., Tian, E., Tytarenko, R., Zhang, Q., Stein, C., Barlogie, B., Epstein, J., Heuck, C., Artesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosis. Oncotarget, 5, 2014, 4118.
39. [39] Zhao, C., Qin, G., Gao, W., Chen, J., Liu, H., Xi, G., Li, T., Wu, S., Chen, T., Potent proapoptotic actions of dihydroartemisinin in gemcitabine-resistant A549 cells. Cell Signal. 26 (2014), 2223–2233.
40. [40] Gao, W., Xiao, F., Wang, X., Chen, T., Artemisinin induces A549 cell apoptosis dominantly via a reactive oxygen species-mediated amplification activation loop among caspase-9, -8 and -3. Apoptosis 18 (2013), 1201–1213.
41. [41] Onuki, R., Nagasaki, A., Kawasaki, H., Baba, T., Uyeda, T.Q., Taira, K., Confirmation by FRET in individual living cells of the absence of significant amyloid β-mediated caspase 8 activation. Proc. Natl. Acad. Sci. USA 99 (2002), 14716–14721.
42. [42] Takikawa, Y., Miyoshi, H., Rust, C., Roberts, P., Siegel, R., Mandal, P.K., Millikan, R.E., Gores, G.J., The bile acid-activated phosphatidylinositol 3-kinase pathway inhibits Fas apoptosis upstream of bid in rodent hepatocytes. Gastroenterology 120 (2001), 1810–1817.
43. [43] Efferth, T., Benakis, A., Romero, M.R., Tomicic, M., Rauh, R., Steinbach, D., Hafer, R., Stamminger, T., Oesch, F., Kaina, B., Marschall, M., Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic. Biol. Med. 37 (2004), 998–1009.
44. [44] Chen, S., Dai, Y., Harada, H., Dent, P., Grant, S., Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res. 67 (2007), 782–791.
45. [45] Komarov, P.G., Komarova, E.A., Kondratov, R.V., Christov-Tselkov, K., Coon, J.S., Chernov, M.V., Gudkov, A.V., A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285 (1999), 1733–1737.
46. [46] Zhu, A.X., Sahani, D.V., di Tomaso, E., Duda, D., Sindhwani, V., Yoon, S.S., Blaszkowsky, L.S., Clark, J.W., Ryan, D.P., Jain, R.K., A phase II study of sunitinib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol., 25, 2007, 213S.
47. [47] Qin, S., Bai, Y., Lim, H.Y., Thongprasert, S., Chao, Y., Fan, J., Yang, T.-S., Bhudhisawasdi, V., Kang, W.K., Zhou, Y., Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J. Clin. Oncol. 31 (2013), 3501–3508.
48. [48] Bruix, J., Sherman, M., Management of hepatocellular carcinoma. Hepatology 42 (2005), 1208–1236.
49. [49] Ba, Q., Zhou, N., Duan, J., Chen, T., Hao, M., Yang, X., Li, J., Yin, J., Chu, R., Wang, H., Dihydroartemisinin exerts its anticancer activity through depleting cellular iron via transferrin receptor-1. PLoS One, 7, 2012, e42703.
50. [50] Lu, J.-J., Meng, L.-H., Cai, Y.-J., Chen, Q., Tong, L.-J., Lin, L.-P., Ding, J., Dihydroartemisinin induces apoptosis in HL-60 leukemia cells dependent of iron and p38 mitogen-activated protein kinase activation but independent of reactive oxygen species. Cancer Biol. Ther. 7 (2008), 1017–1023.
51. [51] Kijima, H., Sawada, T., Tomosugi, N., Kubota, K., Expression of hepcidin mRNA is uniformly suppressed in hepatocellular carcinoma. BMC Cancer, 8, 2008, 1.
52. [52] Tan, M.G.K., Kumarasinghe, M.P., Wang, S.M., Ooi, L.L.P., Aw, S.E., Hui, K.M., Modulation of iron-regulatory genes in human hepatocellular carcinoma and its physiological consequences. Exp. Biol. Med. 234 (2009), 693–702.
53. [53] Tseng, H.-H., Chang, J.-G., Hwang, Y.-H., Yeh, K.-T., Chen, Y.-L., Yu, H.-S., Expression of hepcidin and other iron-regulatory genes in human hepatocellular carcinoma and its clinical implications. J. Cancer Res. Clin. 135 (2009), 1413–1420.
54. [54] Meneghini, R., Iron homeostasis, oxidative stress, and DNA damage. Free Radic. Biol. Med. 23 (1997), 783–792.
55. [55] Asano, T., Komatsu, M., Yamaguchi-Iwai, Y., Ishikawa, F., Mizushima, N., Iwai, K., Distinct mechanisms of ferritin delivery to lysosomes in iron-depleted and iron-replete cells. Mol. Cell. Biol. 31 (2011), 2040–2052.
56. [56] Puisieux, A., Ji, J., Guillot, C., Legros, Y., Soussi, T., Isselbacher, K., Ozturk, M., p53-mediated cellular response to DNA damage in cells with replicative hepatitis B virus. Proc. Natl. Acad. Sci. USA 92 (1995), 1342–1346.
57. [57] Müller, M., Strand, S., Hug, H., Heinemann, E.-M., Walczak, H., Hofmann, W.J., Stremmel, W., Krammer, P.H., Galle, P.R., Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Investig., 99, 1997, 403.
58. [58] Surget, S., Khoury, M.P., Bourdon, J.-C., Uncovering the role of p53 splice variants in human malignancy: a clinical perspective. Onco Targets Ther. 7 (2013), 57–68.
59. [59] Wang, Y., Qiu, Z., Zhou, B., Liu, C., Ruan, J., Yan, Q., Liao, J., Zhu, F., In vitro antiproliferative and antioxidant effects of urolithin A, the colonic metabolite of ellagic acid, on hepatocellular carcinomas HepG2 cells. Toxicol. In Vitro 29 (2015), 1107–1115.
60. [60] Stiuso, P., Bagarolo, M.L., Ilisso, C.P., Vanacore, D., Martino, E., Caraglia, M., Porcelli, M., Cacciapuoti, G., Protective effect of tyrosol and S-Adenosylmethionine against ethanol-induced oxidative stress of Hepg2 cells involves Sirtuin 1, P53 and Erk1/2 signaling. Int. J. Mol. Sci., 17, 2016, 622.
61. [61] Liu, D., Xu, Y., p53, oxidative stress, and aging. Antioxid. Redox Signal. 15 (2011), 1669–1678.
62. [62] Sablina, A.A., Budanov, A.V., Ilyinskaya, G.V., Agapova, L.S., Kravchenko, J.E., Chumakov, P.M., The antioxidant function of the p53 tumor suppressor. Nat. Med. 11 (2005), 1306–1313.
63. [63] Zhang, F., Wang, W., Tsuji, Y., Torti, S.V., Torti, F.M., Post-transcriptional modulation of iron homeostasis during p53-dependent growth arrest. J. Biol. Chem. 283 (2008), 33911–33918.
64. [64] Ba, Q., Hao, M., Huang, H., Hou, J., Ge, S., Zhang, Z., Yin, J., Chu, R., Jiang, H., Wang, F., Chen, K., Liu, H., Wang, H., Iron deprivation suppresses hepatocellular carcinoma growth in experimental studies. Clin. Cancer Res. 17 (2011), 7625–7633.